Targeting HIV latency: Pharmacologic strategies toward eradication

Drug Discovery Today

Volumn 18, Issue 11-12, 2013, Pages 541-551

  Xing, Sifei ^a   Siliciano, Robert F ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; 5 AZA 2' DEOXYCYTIDINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; 8 QUINOLINOL; APICIDIN; BELINOSTAT; BRYOSTATIN 1; BUTYRIC ACID; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; DISULFIRAM; DNA METHYLTRANSFERASE; GIVINOSTAT; HEXAMETHYLENEBISACETAMIDE; HISTONE DEACETYLASE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INGENOL MEBUTATE; JUGLONE; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; OXAMFLATIN; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN KINASE C; SYNAPTOTAGMIN I; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR SP1; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ANTIVIRAL ACTIVITY; CALCIUM TRANSPORT; CD4+ T LYMPHOCYTE; CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; DRUG STRUCTURE; DRUG TARGETING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS REACTIVATION;

ANTI-HIV AGENTS; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; METHYLTRANSFERASES; POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B; VIRUS LATENCY;

EID: 84878873135     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.12.008     Document Type: Review

References (87)

1. J.N. Blankson The challenge of viral reservoirs in HIV-1 infection Annu. Rev. Med. 53 2002 557 593
2. T.W. Chun Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection Nature 387 1997 183 188
3. D. Finzi Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 278 1997 1295 1300
4. J.K. Wong Recovery of replication competent HIV despite prolonged suppression of plasma viremia Science 278 1997 1291 1295
5. J.D. Siliciano Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4T cells Nat. Med. 9 2003 727 728
6. M.C. Strain Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence Proc. Natl. Acad. Sci. U. S. A. 100 2003 4819 4824
7. J.M. Prins Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy AIDS 13 1999 2405 2410
8. Y. Han Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough Cell Host Microbe 4 2008 134 146
9. L. Shan Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model J. Virol. 85 2011 5384 5393
10. T. Lenasi Transcriptional interference antagonizes proviral gene expression to promote HIV latency Cell Host Microbe 4 2008 123 133
11. T.M. Folks Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency Science 231 1986 600 602
12. T.M. Folks Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line Science 238 1987 800 802
13. A. Jordan HIV reproducibly establishes a latent infection after acute infection of T cells in vitro EMBO J. 22 2003 1868 1877
14. O. Kutsch Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency J. Virol. 76 2002 8776 8786
15. + cells is due to epigenetic transcriptional silencing and P-TEFb restriction J. Virol. 84 2010 6425 6437
16. A. Marini An in vitro system to model the establishment and reactivation of HIV-1 latency J. Immunol. 181 2008 7713 7720
17. A. Bosque, and V. Planelles Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells Methods 53 2011 54 61
18. + T cells to HIV-1 infection: a novel model of HIV-1 latency Blood 110 2007 4161 4164
19. H.C. Yang Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation J. Clin. Invest. 119 2009 3473 3486
20. M. Lusic Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter EMBO J. 22 2003 6550 6561
21. L. Ylisastigui Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors J. Infect. Dis. 190 2004 1429 1437
22. S. Matalon Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir Mol. Med. 17 2011 466 472
23. N.M. Archin Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy Nature 487 2012 482 485
24. I. du Chene Suv39H1 and HP1γ are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency EMBO J. 26 2007 424 435
25. + T cells from HIV-1-infected HAART-treated patients AIDS 26 2012 1473 1482
26. S.E. Kauder Epigenetic regulation of HIV-1 latency by cytosine methylation PLoS Pathog. 5 2009 e1000495
27. J. Blazkova CpG methylation controls reactivation of HIV from latency PLoS Pathog. 5 2009 e1000554
28. + T cells from infected individuals receiving antiretroviral therapy J. Virol. 86 2012 5390 5392
29. M. Barboric Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription Nucleic Acids Res. 35 2007 2003 2012
30. M. Barboric Interplay between 7SK snRNA and oppositely charged regions inHEXIM1 direct the inhibition of P-TEFb EMBO J. 24 2005 4291 4303
31. J.H. Yik Inhibition of P-TEFb (CDK9/cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA Mol. Cell 12 2003 971 982
32. A.A. Michels Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor EMBO J. 23 2004 2608 2619
33. K.S. Keedy A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression J. Virol. 83 2009 4749 4756
34. X. Contreras Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells J. Biol. Chem. 284 2009 6782 6789
35. K. Huber Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells J. Biol. Chem. 286 2011 22211 22218
36. C. Van Lint Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histoneacetylation EMBO J. 15 1996 1112 1120
37. H. Ying Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines Int. J. Mol. Med. 26 2010 265 272
38. H. Yin Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells Mol. Biol. Rep. 38 2011 5071 5078
39. S. Matalon The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro J. Acquir. Immune Defic. Syndr. 54 2010 1 9
40. B.S. Choi Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1 AIDS 24 2010 609 611
41. L. Ylisastigui Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression AIDS 18 2004 1101 1108
42. F. Kashanchi Rapid and sensitive detection of cell-associated HIV-1 in latently infected cell lines and in patient cells using sodium-n-butyrate induction and RT-PCR J. Med. Virol. 52 1997 179 189
43. S. Lin HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells Curr. HIV Res. 9 2011 202 208
44. M. Paris Histone deacetylase inhibitors: from bench to clinic J. Med. Chem. 51 2008 1505 1529
45. G. Lehrman Depletion of latent HIV-1 infection in vivo: a proof-of-concept study Lancet 366 2005 549 555
46. J.D. Siliciano Stability of the latent reservoir for HIV-1 in patients receiving valproic acid J. Infect. Dis. 195 2007 833 836
47. N. Sagot-Lerolle Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir AIDS 22 2008 1125 1129
48. + cell infection PLoS ONE 5 2010 e9390
49. N.M. Archin Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid AIDS Res. Hum. Retroviruses 25 2009 207 212
50. J. Friedman Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2 J. Virol. 85 2011 9078 9089
51. K. Imai Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294 J. Biol. Chem. 285 2010 16538 16545
52. W. Bernhard The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response FEBS Lett. 585 2011 3549 3554
53. P. Fenaux Inhibitors of DNA methylation: beyond myelodysplastic syndromes Nat. Clin. Pract. Oncol. 2 Suppl. 1 2005 36 44
54. G. Fernandez, and S.L. Zeichner Cell line-dependent variability in HIV activation employing DNMT inhibitors Virol. J. 7 2010 266
55. S. Williams Prostratin antagonizes HIV latency by activating NF-kB J. Biol. Chem. 279 2004 42008 42017
56. S. Zayed New tigliane and daphnane derivatives from Pimelea prostrata and Pimelea simplex Experientia 33 1977 1554 1555
57. S. Bocklandt Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate Antiviral Res. 59 2003 89 98
58. N. Márquez Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation Biochem. Pharmacol. 75 2008 1370 1380
59. J. Kulkosky Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART Blood 98 2001 3006 3015
60. Z. Szallasi Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin Cancer Res. 53 1993 2507 2512
61. A. Biancotto Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue J. Virol. 78 2004 10507 10515
62. Y.D. Korin Effects of prostratin on T-Cell activation and human immunodeficiency virus latency J. Virol. 76 2002 8118 8123
63. J. Kulkosky Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents AIDS Res. Hum. Retroviruses 20 2004 497 505
64. D.H. Hamer Rational design of drugs that induce human immunodeficiency virus replication J. Virol. 77 2003 10227 10236
65. D. Warrilow HIV type 1 inhibition by protein kinase C modulatory compounds AIDS Res. Hum. Retroviruses. 22 2006 854 864
66. E. Ersvaer The protein kinase C agonist PEP005 (Ingenol 3-Angelate) in the treatment of human cancer: a balance between efficacy and toxicity Toxins (Basel) 2 2010 174 194
67. L.M. Bedoya SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro Biochem. Pharmacol. 77 2009 965 978
68. L. Avila Effects of diterpenes from latex of Euphorbia lactea and Euphorbia laurifolia on human immunodeficiency virus type 1 reactivation Phytochemistry 71 2009 243 248
69. M. Daoubi Isolation of new phenylacetylingol derivatives that reactivate HIV-1 latency and a novel spirotriterpenoid from Euphorbia officinarum latex Bioorg. Med. Chem. 15 2007 4577 4584
70. L. Huang Picomolar dichotomous activity of gnidimacrin against HIV-1 PLoS ONE 6 2011 e26677
71. R. Mehla Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner PLoS ONE 5 2010 e11160
72. S.A. Trushin Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCα and PKCθ J. Virol. 79 2005 9821 9830
73. J. Vlach, and P.M. Pitha Hexamethylene bisacetamide activates the human immunodeficiency virus type 1 provirus by an NF-κB-independent mechanism J. Gen. Virol. 74 1993 2401 2408
74. X. Contreras HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription PLoS Pathog. 3 2007 1459 1469
75. + T cells J. Infect. Dis. 197 2008 1162 1170
76. M.J. Egorin Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion Cancer Res. 47 1987 617 623
77. M. Andreeff Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent Blood 80 1992 2604 2609
78. C. Banerjee BET bromodomain inhibition as a novel strategy for reactivation of HIV-1 J. Leukoc. Biol. 2012 10.1189/jlb.0312165 (Epub ahead of print)
79. Z. Yang Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4 Mol. Cell 19 2005 535 545
80. P. Filippakopoulos Selective inhibition of BET bromodomains Nature 468 2010 1067 1073
81. + T cell model without inducing global T cell activation J. Virol. 85 2011 6060 6064
82. S. Micheva-Viteva High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor J. Biol. Chem. 286 2011 21083 21091
83. + T cell model without inducing global T cell activation J. Antimicrob. Chemother. 67 2012 398 403
84. S. Reuse Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection PLoS ONE 4 2009 e6093
85. J.C. Burnett Combinatorial latency reactivation for HIV-1 subtypes and variants J. Virol. 84 2010 5958 5974
86. L. Shan Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation Immunity 36 2012 491 501
87. M. Shehu-Xhilaga The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells AIDS 23 2009 2047 2059